Targeting MDM2 affects spastin protein levels and functions: implications for HSP treatment

Area of Science:

• Molecular biology
• Neuroscience
• Cell biology

Background:

• Spastin is a microtubule-severing enzyme crucial for cell functions.
• Reduced spastin levels cause Hereditary Spastic Paraplegia (HSP), a neurodegenerative disorder.
• Current HSP treatments lack a cure, necessitating novel therapeutic strategies.

Purpose of the Study:

• To investigate the interaction between MDM2 and spastin.
• To determine MDM2's role in regulating spastin protein levels.
• To explore MDM2 inhibition as a potential therapeutic approach for HSP.

Main Methods:

• Biochemical assays to confirm MDM2-spastin binding.
• Functional experiments to assess spastin regulation by MDM2.
• Cellular studies using MDM2 inhibitor Nutlin-3a in spastin-deficient cells.

Main Results:

• MDM2 directly interacts with the spastin MT-interacting and trafficking (MIT) domain.
• MDM2 regulates spastin protein levels post-transcriptionally, independent of its E3 ubiquitin ligase activity.
• Nutlin-3a treatment restored spastin levels and functions, including cytokinetic abscission and transferrin receptor sorting.

Conclusions:

• MDM2 is identified as a novel interactor of spastin.
• MDM2 represents a potential druggable target for modulating spastin levels.
• Targeting MDM2 offers a promising therapeutic avenue for Hereditary Spastic Paraplegia.